NEW YORK, Jan 25 (Reuters) - Amgen Inc. (AMGN.O: Quote, Profile , Research) on Thursday disclosed negative findings in studies of its Aranesp anemia drug and Vectibix colon cancer treatment, including a higher risk of death among cancer patients not undergoing chemotherapy who were treated with Aranesp.
